Rosetta Genomics Ltd. appointed Kevin Watson to the newly established role of Director, Reimbursement-Managed Care. Mr. Watson joins Rosetta Genomics from competing molecular diagnostics company, bioTheranostics, where for two years he was the Director of Reimbursement.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | +9,900.00% | -.--% | -.--% |
2018 | Genoptix, Inc. cancelled the acquisition of Rosetta Genomics Ltd.. | CI |
2018 | Rosetta Genomics Ltd.(NasdaqCM:ROSG) dropped from NASDAQ Composite Index | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 592 | |
+35.80% | 5.15TCr | |
-6.38% | 3.9TCr | |
+34.78% | 3.89TCr | |
-12.11% | 2.67TCr | |
+12.09% | 2.61TCr | |
-16.12% | 1.99TCr | |
+42.57% | 1.37TCr | |
+30.80% | 1.24TCr | |
-3.60% | 1.17TCr |
- Stock Market
- Equities
- ROSGQ Stock
- News Rosetta Genomics Ltd.
- Rosetta Genomics Ltd. Appoints Kevin Watson as Director, Reimbursement-Managed Care